Yuehan Zhang1, Tim Waterboer2, Michael Pawlita2, Elizabeth Sugar1, Howard Minkoff3, Ross D Cranston4, Dorothy Wiley5, Robert Burk6, Susheel Reddy7, Joseph Margolick1, Howard Strickler6, Kathleen Weber8, Maura Gillison9, Gypsyamber D'Souza10. 1. Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD 21205, United States. 2. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. 3. Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219, United States. 4. University of Pittsburgh, 3520 Fifth Avenue, Pittsburgh, PA 15213, United States. 5. University of California, Los Angeles, 2-256 Factor Bldg., Los Angeles, CA 90095-1702, United States. 6. Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, United States. 7. Northwestern University, 645 N Michigan Ave., Chicago, IL 60611, United States. 8. CORE Center at John H. Stroger Jr. Hospital of Cook County, 2225 W Harrison St., Chicago, IL 60612, United States. 9. Ohio State University Comprehensive Cancer Center, 420 W 12th Ave., Columbus, OH 43210, United States. 10. Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD 21205, United States. Electronic address: gdsouza2@jhu.edu.
Abstract
INTRODUCTION: Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. METHODS: Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n=54), or incident (n=39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n=155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. RESULTS: HPV16 E6 seropositivity (7.5% vs 0.7%; p=0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR=14.6 95%CI, 1.7-122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p=1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR=0.65 95% CI, 0.16-2.70). Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. DISCUSSION: HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.
INTRODUCTION:Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. METHODS: Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n=54), or incident (n=39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n=155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. RESULTS:HPV16 E6 seropositivity (7.5% vs 0.7%; p=0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR=14.6 95%CI, 1.7-122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p=1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR=0.65 95% CI, 0.16-2.70). Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. DISCUSSION: HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.
Authors: Krystle A Lang Kuhs; Devasena Anantharaman; Tim Waterboer; Mattias Johansson; Paul Brennan; Angelika Michel; Martina Willhauck-Fleckenstein; Mark P Purdue; Ivana Holcátová; Wolfgang Ahrens; Pagona Lagiou; Jerry Polesel; Lorenzo Simonato; Franco Merletti; Claire M Healy; Kristina Kjaerheim; David I Conway; Tatiana V Macfarlane; Peter Thomson; Xavier Castellsagué; Ariana Znaor; Amanda Black; Wen-Yi Huang; Vittorio Krogh; Antonia Trichopoulou; H B As Bueno-de-Mesquita; Françoise Clavel-Chapelon; Elisabete Weiderpass; Johanna Ekström; Elio Riboli; Anne Tjønneland; María-José Sánchez; Ruth C Travis; Allan Hildesheim; Michael Pawlita; Aimée R Kreimer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01-26 Impact factor: 4.254
Authors: J Mork; A K Lie; E Glattre; G Hallmans; E Jellum; P Koskela; B Møller; E Pukkala; J T Schiller; L Youngman; M Lehtinen; J Dillner Journal: N Engl J Med Date: 2001-04-12 Impact factor: 91.245
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Daniel C Beachler; Kathleen M Weber; Joseph B Margolick; Howard D Strickler; Ross D Cranston; Robert D Burk; Dorothy J Wiley; Howard Minkoff; Susheel Reddy; Emily E Stammer; Maura L Gillison; Gypsyamber D'Souza Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-01 Impact factor: 4.254
Authors: Elaine M Smith; Justine M Ritchie; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Lubomir P Turek; Eva Hamsikova Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Karen S Anderson; Kristina R Dahlstrom; Julia N Cheng; Rizwan Alam; Guojun Li; Qingyi Wei; Neil D Gross; Diego Chowell; Marshall Posner; Erich M Sturgis Journal: Oral Oncol Date: 2015-05-06 Impact factor: 5.337
Authors: Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza Journal: Am J Epidemiol Date: 2014-12-04 Impact factor: 4.897
Authors: Zoe R Edelstein; Stephen M Schwartz; Stephen Hawes; James P Hughes; Qinghua Feng; Michael E Stern; Sandra O'Reilly; Shu-Kuang Lee; Long Fu Xi; Laura A Koutsky Journal: Sex Transm Dis Date: 2012-11 Impact factor: 2.830
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui Journal: Front Immunol Date: 2021-01-08 Impact factor: 7.561